Skip to content
A Neuralink participant, partly out of frame at the right edge, sits beside two laptops, one showing neural signal traces and the other a grid-based cursor-control task with a bits-per-second score of 4.18.

Cyborgs

Neuralink registers PRIME2 trial, adding chronic stroke to its implant studies

Image: Neuralink / website · press-kit

Published · North America

Neuralink listed PRIME2 on ClinicalTrials.gov on 10 November 2026: up to 10 adults with spinal cord injury, ALS or chronic stroke, starting at the University of Miami.

Neuralink registered a new early feasibility study, PRIME2, on ClinicalTrials.gov on 10 November 2026 (NCT07929792). It will place the company's N1 brain-computer interface with its R1 surgical robot, which inserts the implant's electrode threads, and test whether participants can control external devices.

The record lists up to 10 adults aged 18 or older with severe upper-limb impairment from spinal cord injury, ALS or chronic ischemic stroke. Chronic stroke is a new population for Neuralink's registered trials. Status is recruiting, with an estimated start in November 2026. One site is listed, the University of Miami; the study summary mentions up to five U.S. sites.

A registry entry is not a result: it names no participant, no implant date and no outcome data.

Sources

On RobotShop

Wearable Technology